Jack Nielsen - Nov 29, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Director
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Nov 29, 2022
Transactions value $
-$7,686,960
Form type
4
Date filed
12/1/2022, 06:52 PM
Previous filing
Nov 22, 2022
Next filing
Dec 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Sale -$1.23M -21.3K -0.76% $57.82 2.79M Nov 29, 2022 See Footnote F1, F2, F3
transaction HRMY Common Stock Sale -$2.51M -42.7K -1.53% $58.93 2.75M Nov 30, 2022 See Footnote F1, F3, F4
transaction HRMY Common Stock Sale -$3.94M -65.7K -2.39% $60.00 2.68M Dec 1, 2022 See Footnote F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.
F2 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $57.21 to $58.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
F4 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $57.5 to $59.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.